Q3 EPS Estimates for Journey Medical Cut by HC Wainwright

Journey Medical Corporation (NASDAQ:DERM) – HC Wainwright decreased their Q3 2026 earnings estimates for shares of Journey Medical in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of $0.01 per share for the quarter, down from their prior forecast of $0.03. The consensus estimate for Journey Medical’s current full-year earnings is $0.17 per share. HC Wainwright also issued estimates for Journey Medical’s Q4 2026 earnings at $0.02 EPS, FY2027 earnings at $1.07 EPS, FY2028 earnings at $1.66 EPS, FY2029 earnings at $1.81 EPS and FY2030 earnings at $1.92 EPS.

Journey Medical (NASDAQ:DERM) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.01. The firm had revenue of $18.51 million during the quarter, compared to the consensus estimate of $18.36 million. Journey Medical had a negative net margin of 8.95% and a negative return on equity of 20.67%.

Other equities analysts have also recently issued research reports about the company. Wall Street Zen upgraded Journey Medical from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Journey Medical in a research report on Friday, July 17th. Finally, B. Riley Financial reiterated a “buy” rating and set a $15.00 price objective (up from $12.00) on shares of Journey Medical in a research report on Thursday. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Journey Medical currently has a consensus rating of “Hold” and an average price target of $14.00.

Journey Medical Trading Up 3.4%

Shares of NASDAQ DERM opened at $6.65 on Friday. Journey Medical has a 1-year low of $4.31 and a 1-year high of $9.56. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.72 and a quick ratio of 1.47. The business’s 50 day moving average is $6.59 and its two-hundred day moving average is $6.61. The stock has a market capitalization of $183.07 million, a P/E ratio of -30.23 and a beta of 1.08.

Institutional Investors Weigh In On Journey Medical

A number of institutional investors and hedge funds have recently modified their holdings of DERM. Wasatch Advisors LP increased its stake in Journey Medical by 34.0% in the second quarter. Wasatch Advisors LP now owns 2,858,930 shares of the company’s stock worth $20,241,000 after purchasing an additional 725,560 shares during the period. Opaleye Management Inc. increased its stake in Journey Medical by 0.4% in the 4th quarter. Opaleye Management Inc. now owns 975,000 shares of the company’s stock worth $7,517,000 after buying an additional 3,936 shares during the period. J. Goldman & Co LP bought a new stake in Journey Medical during the 4th quarter valued at about $6,155,000. Vanguard Group Inc. boosted its position in Journey Medical by 8.9% in the 3rd quarter. Vanguard Group Inc. now owns 615,229 shares of the company’s stock valued at $4,380,000 after buying an additional 50,241 shares during the period. Finally, Pale Fire Capital SE grew its stake in Journey Medical by 8.4% in the 1st quarter. Pale Fire Capital SE now owns 481,987 shares of the company’s stock worth $2,261,000 after acquiring an additional 37,345 shares in the last quarter. 7.25% of the stock is owned by institutional investors.

Key Headlines Impacting Journey Medical

Here are the key news stories impacting Journey Medical this week:

• Positive Sentiment: Q2 results exceeded expectations: Journey Medical reported a loss of $0.01 per share versus the $0.02 consensus loss, while revenue of $18.51 million topped estimates of $18.36 million. The earnings beat suggests better-than-expected operating performance. Journey Medical Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Emrosi momentum remained strong: Management highlighted a 20% sequential increase for Emrosi, which reached $8.1 million, along with 38% high-quality coverage. The company also signaled continued average selling price gains in the second half of 2026, supporting the growth outlook. Journey Medical Signals Continued ASP Gains
• Positive Sentiment: B. Riley raised its price target: The firm reaffirmed a “buy” rating and increased its target to $15 from $12, implying substantial potential upside from the stock’s recent $6.65 level. This reinforces the bullish view that Emrosi and the company’s dermatology portfolio can drive future growth.
• Neutral Sentiment: Long-term profitability remains a key catalyst: HC Wainwright still projects positive EPS from 2027 onward, including $1.07 in 2027 and $1.66 in 2028, but the estimates are now below its prior forecasts. Investors will likely focus on whether improving product sales can translate into sustained profitability.
• Negative Sentiment: HC Wainwright cut earnings estimates across the forecast period: Q3 2026 EPS was reduced to $0.01 from $0.03 and Q4 to $0.02 from $0.07. Estimates for fiscal 2027 through 2030 were also lowered, including 2030 EPS to $1.92 from $1.98. The cuts indicate expectations for slower near-term earnings growth and are the primary bearish factor in the news flow.

Journey Medical Company Profile

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.